|
Stockprowler
picks NNLX for January 2008
As the value of the dollar continues to plummet in the world market,
watch for the price of oil to reach unthinkable levels. You think
$100 a barrel oil is bad and just a temporary aberration? Look for
$150 a barrel oil by July 2008 as the Arabs demand more worth-less
U.S. dollars for their oil. And as oil becomes a more and more expensive
source of energy, other fuel alternatives become viable. In the Stockprowler
crystal ball we see hydrogen eventually replacing oil as the primary
source of energy in our increasingly energy hungry world. Hydrogen
is the most abundant element in the universe and also has the highest
energy content per unit weight of any known fuel. The bad news is
that it rarely occurs by itself in nature. It is mostly found combined
with other elements from which it must be separated. The good news
is that once extracted, hydrogen in liquid form is the ultimate clean
and highly compacted energy carrier. Presently, the cost of commercially
generating hydrogen is almost $5.00 per equivalent gallon of gasoline.
Enter
NanoLogix (OTC: NNLX) trading at around 10 cents. NanoLogix has patented
technology to inexpensively produce hydrogen from biomass. It is rumored
that its commercial process can deliver hydrogen at less than $1.00
per equivalent gallon of gasoline. NanoLogix is presently operating
a hydrogen bioreactor at Welch's Foods near Erie, Pennsylvania to
produce hydrogen from Welch's sugar-rich wastewater stream. R&D into
a next-generation commercial demonstration bioreactor for Welch's
is ongoing at Gannon University in Erie. This effort has been solely
funded by NanoLogix for the prototype bioreactor development, with
major funding from Welch's anticipated for the next stage. NanoLogix
has signed an agreement with the City of Erie Wastewater Treatment
Plant for a prototype bioreactor installation based upon NanoLogix's
patents and designed to extract hydrogen from activated sewage sludge.
The Company's goal is to capitalize on the potential energy value
of over 170 million tons of sewer sludge generated annually in the
United States. NanoLogix plans to install the prototype in the Erie
facility in the spring of 2008.
NanoLogix
has 31 granted patents and 36 patents pending for bioreactor-based
hydrogen production, revolutionary rapid medical testing technologies,
potential treatments for sepsis and cancer, and bioremediation. NanoLogix
has also filed 7 patents for its new BioNanoChannel™ technology for
rapid microorganism (bacteria/spores) detection and identification.
This is a revolutionary, cutting-edge technology developed by Nanologix
that enables the identification and/or growth of microorganism cultures
in 1 to 7 hours. BioNanoChannel™ technology utilizes extremely small
nano-sized channels to trap microorganisms and then applies proprietary
NanoLogix techniques covered in the patent to detect and/or identify
the microorganisms in concentrations as small as a single cell.
This
technology is in sharp contrast to the traditional method for detection
and growth utilizing Petri dishes --- a device invented in 1877 ---
a process that normally takes 24 to 72 hours to identify or culture
a microorganism. The importance of this is that in a critical infection
situation, the ability to achieve rapid detection and identification
of microorganisms can mean the difference between life and death.
NanoLogix believes that BioNanoChannel™ technology has the potential
to capture much of the current global multi-billion dollar Petri dish
market.
The company is in talks with the US Department of Defense
for providing of BioNanoChannel technology for use in the confirmation
of effectiveness of decontamination efforts in the event of biological
attacks, currently specific to anthrax, but with the potential for
use in the event of use of other biological agents or toxins. NanoLogix
has been contacted by an international pharmaceutical company and
asked to provide information and assistance in reducing the time to
test pharmaceutical samples to less than 24 hours --- a task that
is easily within the capabilities of the BioNanoChannel technology.
NanoLogix
is currently working with another unnamed company to ascertain
whether a BioNanoChannel device can provide a method for reducing
the time necessary for the identification and detection of protein
markers that occur early on in victims of Traumatic Brain Injury (TBI).
Public attention has recently focused on TBI due to the publicity
received by returning veterans from both Afghanistan and Iraq who
have been exposed to various types of blast injuries from Improvised
Explosive Devices (IED). In fact, it is a condition that affects over
1,500,000 victims of accidents and violence each year in the United
States alone. The research team's initial findings have been positive.
Earlier detection of these protein markers may lead to accelerated
treatment and reduced long term negative effects on those who suffer
from these potentially debilitating injuries.
NanoLogix
has the near-term potential to capitalize on its rapid-detection technology,
as evidenced by recent and ongoing government and corporate interest.
There is longer term potential for revenue from both the hydrogen
bioreactor technology use in industrial and wastewater treatment plant
settings, and in sales of medical and environmental test kit technology
through NutraPharma Corp. Nutra Pharma Corp. (OTCBB: NPHC) is a biotechnology
company that is developing drugs for HIV and Multiple Sclerosis (MS),
and recently announced that it has expanded its licensing agreement
with NanoLogix, Inc.
NanoLogix
has submitted international patent applications for BioNanoChannel™
and Hydrogen Bioreactor technology protection in China, India, Brazil,
and the EU (European Union). These filings are in anticipation of
the global roll-out of the company's rapid BioNanoChannel™ bacteria/microorganism
detection technology and also contribute to the protection of NanoLogix's
ongoing Hydrogen Bioreactor development.
Further information on NanoLogix, Inc. is available at www.nanologixinc.com
Well, all right, that's it for now…
place your bets, sit back and relax. Remember, this is speculation
not investing and quite often we get rewarded BIG for taking a chance…
Stockprowler.com
does not receive compensation from companies we profile or from third
parties... we never have and never will. We use our own money when
we buy stocks, and even though we usually take a position in a stock
before we profile a company, our purchases are small relative to the
public float so that the effect on the stock price when we buy or
sell is minimal. Please read our full disclaimer.
Also,
contrary to a commonly held belief, Stockprowler does not have access
to insider information, nor do we want to because trading on insider
information is illegal! All information contained in our reports is
available in the public record... and any written or verbal communication
with company CEOs/IR people strictly adheres to this rule.
Readers
are urged to read the company SEC filings and do their own due diligence
before investing in this or any other stock.
Good
Trading... Stockprowler
|
